"Loading Stock Price & Valuation Data ..."
Unlock News Summary by Subscribing to iPick.ai Premium!
Ask anything related to ATHA. [ FAQ on what and how to ask] For non-ATHA questions, click the logo in the upper-right corner to return to the main page and ask there.
CEO:Dr. Mark J. Litton M.B.A., Ph.D.
Headquarter: 18706 North Creek Parkway, Suite 104, Bothell, WA, United States, 98011
Industry: Biotechnology, Employees: 26
Athira Pharma, Inc., clinical-stage biopharmaceutical company, focuses on developing small molecules to restore neuronal health and slow neurodegradation. Its product pipeline includes ATH-1105 for the treatment of amyotrophic lateral sclerosis, which is in phase 1 clinical trial; ATH-1020 for the treatment of neurodegenerative diseases, which is phase 1 clinical trial, as well as early compounds which is in preclinical phase. The company was formerly known as M3 Biotechnology, Inc. and changed its name to Athira Pharma, Inc. in April 2019. Athira Pharma, Inc. was incorporated in 2011 and is headquartered in Bothell, Washington.
My Watchlist
